A single dose of sildenafil, a blood vessel widening vasodilator, prevented rebound pulmonary hypertension and significantly reduced the duration of mechanical ventilation in intensive care unit (ICU) infants being withdrawn from inhaled nitric oxide therapy.
“Cardiovascular disease remains our country’s biggest killer,” said Minister Clement. “Canada’s new government is following through on our promise to develop a heart health strategy. The strategy developed will ensure crucial information on prevention and treatment is available quickly and effectively to all provinces and territories. A new Heart Health Strategy will save lives.”
New data presented today show patients taking pramipexole (Mirapexin?/ Sifrol?) can experience significant improvements in a broad range of symptoms associated with Restless Legs Syndrome (RLS).1 In an additional study presented today, pramipexole was also shown to be well tolerated in RLS patients affected by concomitant diseases, which are commonly experienced in this patient group.2 The results of the studies were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.
As we all know, life is very stressful these days, specially in corporate sector. People work more, skip meals and miss sleep. Everyone is trying to achieve the targets, and then result is stress. In stress, mind grows all the negative thoughts like fear, anger, guilt, anxiety, frustration, and so on. And in response to all these, body produces catecholamines which results in increased acidity, faster beating of hearts, tensing of muscles, shooting of blood pressure and restless mind. Finally, all these end up with hypertension, thyroid problems, diabetes mellitus, and many other chronic diseases.
The experience of racial discrimination may be a key factor in explaining why African Americans have higher rates of obesity and suffer at higher rates from such diseases as diabetes and cardiovascular disorders, according to UCLA researchers. Repeated responses to such discrimination — which include elevated blood pressure and heart rate — can cause enormous stress on a person’s mental and physical health, according to research scheduled to be published in Volume 58 of the Annual Review of Psychology.
There may be as many as 70 million Americans with prehypertension. If these people can be treated pharmacologically to avoid or delay progression to clinical hypertension, there would be significant benefits to them and the overall health of the population. The recent TROPHY study seems to lead to that conclusion. However, two editorials published in the November issue of the American Journal of Hypertension emphatically argue that the study is flawed and the conclusions reached are misleading.
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted an electronic New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Junovan(TM) (mifamurtide for injection), requesting approval for its use in the treatment of newly diagnosed resectable high grade osteosarcoma patients following surgical resection in combination with multiple agent chemotherapy.
Bayer HealthCare (BHC) and Topsun Science and Technology Co., Ltd. (Topsun, 600771.SS) together announced that BHC’s Consumer Care Division has signed an agreement in China to acquire the Western over-the-counter (OTC) cough and cold portfolio of Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co., Ltd. for the consideration of RMB 1,072 million (approximately EUR 103 million) plus contingent payments of RMB 192 million (approximately EUR 19 million) subject to fulfilment of certain performance criteria.
African-American women have the highest mortality rate for idiopathic pulmonary arterial hypertension (IPAH), according to new research. The study, presented at CHEST 2006, the 72nd annual international scientific assembly of the American College of Chest Physicians (ACCP), revealed that racial disparities exist in pulmonary hypertension mortality and morbidity, with African-American women exhibiting the highest mortality rate when compared with all other groups.
Ottawa will invest $8.4-million over the next two years to develop a new heart health strategy, the Health Minister says. The money will initially be used to determine the extent of cardiovascular disease in Canada, and hypertension in particular, and then to shape a plan of attack, Tony Clement said.